Skip to main content
TipRanks
Go Ultimate75% OFF

Concord Medical Services (CCM) AI Stock Analysis

108 Followers
CCM

Concord Medical Services

(NYSE:CCM)

Select Model
Rating:39Underperform
Price Target:$3.50▼(-3.05% Downside)
Action:downgraded
Date:09/18/26

Concord Medical Services scores near the bottom of the range, driven primarily by severe financial distress: negative stockholders' equity of RMB -2.1B, RMB 3.63B of debt against a small revenue base, six straight years of losses, and persistent negative free cash flow. Encouraging 2025 trends — 26% revenue growth, a return to positive gross profit, and materially reduced cash burn — provide only modest offset against going-concern risk. Technicals reinforce the caution, with the stock trading below all major moving averages and negative MACD momentum, though oversold RSI and Stochastic readings hint at potential short-term stabilization. Valuation offers no anchor given negative earnings, no dividend, and negative book value. This remains a highly speculative, distressed situation.

Positive Factors
Revenue reboundThe strong 2025 revenue rebound indicates renewed demand for CCM’s oncology-related services and improved business activity after the prior-year decline. If maintained, higher patient volumes and equipment utilization could provide a foundation for operating improvement across the company’s specialized care network.
Negative Factors
Highly stressed balance sheetVery high debt combined with deeply negative equity materially restricts CCM’s financial flexibility. This capital structure leaves less capacity to fund oncology-center investment internally, absorb operating setbacks, or manage obligations without relying on refinancing, asset actions, or other external financial support.

Concord Medical Services (CCM) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%CCM+0.28%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$522.45K
Dividend Yield
―
Average Volume (3M)
23.67K
Price to Earnings (P/E)
-0.0
Beta (1Y)
1.01
Revenue Growth
20.26%
EPS Growth
69.68%
Country
US
Employees
610
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Concord Medical Services Business Overview & Revenue Model

Company Description

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services includ...

How the Company Makes Money

CCM makes money primarily by delivering and managing oncology-focused clinical services, with revenues historically tied to patient volumes and the utilization of high-end equipment used in cancer diagnosis and treatment. Key revenue streams include:...

Concord Medical Services Financial Statement Overview

Summary

All three statements point to severe distress. Six consecutive years of net losses (cumulative RMB 1.77B), negative gross margins in four of the last five years, and 2025 EBITDA of RMB -72M leave the company far from breakeven despite 26% revenue growth and a marginally positive gross profit. The balance sheet is the weakest link: stockholders' equity is deeply negative at RMB -2.1B against RMB 3.63B of debt (nearly 8x annual revenue), making the company technically insolvent on a book basis. Cash flow has been negative every year since 2020, with 2025 operating cash flow of RMB -202M and free cash flow of RMB -293M, though burn did moderate meaningfully from 2024 levels. The directional improvements are real but insufficient to offset elevated going-concern, restructuring, and dilution risk.

Income Statement

8Very Negative

Balance Sheet

4Very Negative

Cash Flow

6Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue585.66M460.51M383.96M537.40M472.08M485.63M
Gross Profit40.31M25.82M-79.16M-76.61M-152.41M-56.90M
EBITDA-75.84M-71.77M-345.62M-334.53M-392.23M-354.24M
Net Income-124.44M-92.81M-308.24M-297.66M-489.66M-271.43M
Balance Sheet
Total Assets6.55B6.55B6.73B6.05B6.00B6.23B
Cash, Cash Equivalents and Short-Term Investments297.79M297.79M350.85M58.14M158.28M157.39M
Total Debt3.63B3.63B3.93B3.30B3.24B2.73B
Total Liabilities4.70B4.70B5.11B4.31B3.99B3.49B
Stockholders Equity-2.10B-2.10B-2.28B-2.12B-1.86B-1.37B
Cash Flow
Free Cash Flow0-293.16M-808.58M-392.17M-600.47M-1.12B
Operating Cash Flow0-201.82M-397.75M-276.47M-216.69M-359.31M
Investing Cash Flow053.97M-593.44M-47.68M-118.79M-565.98M
Financing Cash Flow0197.23M1.15B257.65M383.09M642.45M

Concord Medical Services Technical Analysis

Technical Analysis SentimentNegative
Last Price3.61

Price Trends

50DMA3.63Negative
100DMA4.13Negative
200DMA4.17Negative

Market Momentum

MACD-0.02Negative
RSI48.56Neutral
STOCH61.43Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Negative. The current price of 3.61 is below the 20-day moving average (MA) of 3.67, below the 50-day MA of 3.63, and below the 200-day MA of 4.17, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.56 is Neutral, neither overbought nor oversold. The STOCH value of 61.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCM.

Concord Medical Services Risk Analysis

Concord Medical Services disclosed 78 risk factors in its most recent earnings report. Concord Medical Services reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.We may have conflicts of interest with our subsidiary Concord Healthcare which is a stand-alone public company.Q4, 2023
2.Concord Healthcare may need to raise more capital, which could dilute our equity stake or impose debt service obligations on Concord Healthcare, if such capital is available at all.Q4, 2023

Concord Medical Services Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CCM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JYNTJYNT59Neutral$91.03M33.3219.28%―7.86%55.56%
CCELCCEL53Neutral$33.62M-18.6015.84%―-1.96%-314.41%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AMSAMS50Neutral$6.88M-3.03-10.19%―4.90%-3.41%
PIIIPIII48Neutral$15.61M-0.09171.75%―7.54%42.43%
DCGODCGO40Underperform$17.37M-0.09-144.87%―-19.22%-254.04%
CCMCCM39Underperform$15.67M-0.035.16%―20.26%69.68%

* Healthcare Sector Average

Performance Comparison

0%100%CCMAMSJYNTCCELDCGOPIIIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CCM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CCMConcord Medical Services3.61-0.36-9.07%
AMSAmerican Shared Hospital Services1.03-1.04-50.24%
JYNTJoint Corp6.65-1.55-18.90%
CCELCryo-Cell International 4.170.153.83%
DCGODocGo, Inc.0.17-0.70-80.05%
PIIIP3 Health Partners Inc.2.15-3.72-63.37%

Concord Medical Services Corporate Events

Concord Medical Names Interim CFO as Wei Jiang Steps Down

Jul 2, 2026

Concord Medical announced that chief financial officer Wei Jiang stepped down from his role effective June 30, 2026, to concentrate on the business and operations of Concord Healthcare Group, the company’s Hong Kong-listed subsidiary. The company emp...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 18, 2026